Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siFi2
- Development stage
- Preclinical
- Lead developer
- MicroCures
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical, Ophthalmic
01
Overview
siFi2 is a topical small interfering RNA (siRNA)-based therapeutic developed by MicroCures. It is designed to accelerate healing of excisional and traumatic wounds by silencing the activity of Fidgetin-Like 2 (FL2), a microtubule-associated protein involved in cell motility. By inhibiting FL2 through RNA interference, siFi2 temporarily enhances the migration of cells essential for tissue repair into areas of injury. Preclinical studies have shown that siFi2 accelerates wound closure and improves healing quality in animal models. The drug has been investigated for applications including burns, myocardial infarction, nerve injury, corneal injuries, spinal cord injuries, and general wound healing[1][3][4].
- Brand names
- siFi2siFi-2siFi 2
- Other names
- FL2-siRNAFL-2-siRNAFL 2-siRNA
02
Targets
FL2 (Fidgetin-like protein 2)
Beyond the preview
Go deeper on siFi2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siFi2.